Top in cardiology: Cerebral blood flow device; road traffic linked to hypertension
Click Here to Manage Email Alerts
A device designed to improve cerebral blood flow was associated with improvements in mild cognitive impairment and Alzheimer’s disease, according to a presenter at the American College of Cardiology Scientific Session.
“Cerebral vascular flow plays a significant role in cognitive performance, and treatments improving cerebral blood flow, such as external counterpulsation, may improve cognitive function,” Patrick M. Moriarty, MD, FACC, FACP, a professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, said in his presentation.
It was the top story in cardiology last week.
Another top story was about the increased risk for hypertension in those with long-term exposure to traffic noise and air pollution.
Read these and more top stories in cardiology below:
Noninvasive treatment improves cerebral blood flow, cognition in mild Alzheimer’s disease
A device designed to improve cerebral blood flow with compression of lower limbs synchronized to the cardiac cycle was tied to improved cognitive performance scores in mild cognitive impairment or Alzheimer’s disease. Read more.
Exposure to road traffic noise may drive hypertension risk
Long-term exposure to road traffic noise was associated with increased incidence of primary hypertension, according to a prospective analysis of U.K. Biobank data. Read more.
Supplements touting CV benefits may be ‘harmful distraction’ from proven solutions
Dietary supplements are big business in the United States and elsewhere, especially when it comes to products marketed to support cardiovascular health. Read more.
Cardiorespiratory fitness, with or without CVD, tied to mortality risk for veterans
Among a cohort of veterans, changes in cardiorespiratory fitness over time reflected reciprocal changes in mortality risk, independent of other comorbidities, highlighting the role of physical activity in health outcomes, data show. Read more.
Where do we go from CLEAR?
In the past decade, there have been major advances in lipid-lowering therapeutics, and another was made apparent in March at the American College of Cardiology Scientific Session. Read more.